Bukreyev Alexander, Collins Peter L
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Laboratory of Infectious Disease, 50 South Drive, Bethesda, MD 20892, USA.
Curr Opin Mol Ther. 2008 Feb;10(1):46-55.
Emerging and re-emerging infectious diseases pose a threat to individuals worldwide and necessitate the development of new vaccines and vaccine platforms. Newcastle disease virus (NDV) is an enveloped cytoplasmic RNA virus of avian origin that is highly attenuated in humans and other primates because of a strong host-range restriction. NDV infects the respiratory tract of non-human primates and appears to remain restricted to that site. As a vaccine vector, NDV induced substantial local and systemic responses against a protein expressed by a foreign gene insert and was protective against pathogen challenge. NDV is antigenically distinct from common human viruses, accommodates foreign sequences with a good degree of stability, can be readily produced in a cell line acceptable for human product development, and exhibits a low incidence of recombination. Because of its natural tropism for the respiratory tract, NDV may be particularly effective for the development of vectored vaccines against respiratory infections as well as infections that can be transmitted through the respiratory tract.
新出现和再次出现的传染病对全球个人构成威胁,因此需要开发新的疫苗和疫苗平台。新城疫病毒(NDV)是一种源自禽类的有包膜细胞质RNA病毒,由于强烈的宿主范围限制,它在人类和其他灵长类动物中高度减毒。NDV感染非人类灵长类动物的呼吸道,并且似乎局限于该部位。作为一种疫苗载体,NDV能引发针对外源基因插入片段所表达蛋白质的强烈局部和全身反应,并对病原体攻击具有保护作用。NDV在抗原性上与常见人类病毒不同,能较好地稳定容纳外源序列,可在适合人类产品开发的细胞系中轻松生产,且重组发生率低。由于其对呼吸道具有天然嗜性,NDV对于开发针对呼吸道感染以及可通过呼吸道传播的感染的载体疫苗可能特别有效。